Close

Here we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.

Driving gene-engineered T cell immunotherapy of cancer

Cell research 27, no. 1 (2017): 38-58.

Johnson, Laura A., and Carl H. June.

This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.

Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.

This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.

Chimeric antigen receptor T cells for sustained remissions in leukemia

New England Journal of Medicine 371.16 (2014): 1507-1517.

Maude, Shannon L., et al

A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.

Chimeric antigen receptor–modified T cells for acute lymphoid leukemia

New England Journal of Medicine 368.16 (2013): 1509-1518.

Grupp, Stephan A., et al.

Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia.

New England Journal of Medicine 365.8 (2011): 725-733.

Porter, David L., et al.

A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

The Lancet 385.9967 (2015): 517-528.

Lee, Daniel W., et al.

A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.

Driving gene-engineered T cell immunotherapy of cancer

Cell research 27, no. 1 (2017): 38-58.

Johnson, Laura A., and Carl H. June.

This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.

Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.

This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.

Chimeric antigen receptor T cells for sustained remissions in leukemia

New England Journal of Medicine 371.16 (2014): 1507-1517.

Maude, Shannon L., et al

A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.

Chimeric antigen receptor–modified T cells for acute lymphoid leukemia

New England Journal of Medicine 368.16 (2013): 1509-1518.

Grupp, Stephan A., et al.

Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia.

New England Journal of Medicine 365.8 (2011): 725-733.

Porter, David L., et al.

A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

The Lancet 385.9967 (2015): 517-528.

Lee, Daniel W., et al.

A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.

Driving gene-engineered T cell immunotherapy of cancer

Cell research 27, no. 1 (2017): 38-58.

Johnson, Laura A., and Carl H. June.

This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.

Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.

This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.

Chimeric antigen receptor T cells for sustained remissions in leukemia

New England Journal of Medicine 371.16 (2014): 1507-1517.

Maude, Shannon L., et al

A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.

Chimeric antigen receptor–modified T cells for acute lymphoid leukemia

New England Journal of Medicine 368.16 (2013): 1509-1518.

Grupp, Stephan A., et al.

Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia.

New England Journal of Medicine 365.8 (2011): 725-733.

Porter, David L., et al.

A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

The Lancet 385.9967 (2015): 517-528.

Lee, Daniel W., et al.

A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.

Driving gene-engineered T cell immunotherapy of cancer

Cell research 27, no. 1 (2017): 38-58.

Johnson, Laura A., and Carl H. June.

This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.

Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.

This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.

Chimeric antigen receptor T cells for sustained remissions in leukemia

New England Journal of Medicine 371.16 (2014): 1507-1517.

Maude, Shannon L., et al

A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.

Chimeric antigen receptor–modified T cells for acute lymphoid leukemia

New England Journal of Medicine 368.16 (2013): 1509-1518.

Grupp, Stephan A., et al.

Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia.

New England Journal of Medicine 365.8 (2011): 725-733.

Porter, David L., et al.

A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

The Lancet 385.9967 (2015): 517-528.

Lee, Daniel W., et al.

A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.


Key Updates

Receive the latest news and insights to your inbox.